Primary |
Acute Myeloid Leukaemia |
50.0% |
Acute Lymphocytic Leukaemia |
16.7% |
Acute Promyelocytic Leukaemia |
14.6% |
Leukaemia |
6.3% |
Oesophageal Varices Haemorrhage |
4.2% |
Acute Myelomonocytic Leukaemia |
2.1% |
Antifungal Prophylaxis |
2.1% |
Conjunctivitis |
2.1% |
Hypertension |
2.1% |
|
Endocarditis |
10.0% |
Haematochezia |
10.0% |
Haematuria |
10.0% |
Rash Generalised |
10.0% |
Sinus Tachycardia |
10.0% |
Acute Pulmonary Oedema |
5.0% |
Cerebellar Ataxia |
5.0% |
Chronic Myelomonocytic Leukaemia |
5.0% |
Multi-organ Failure |
5.0% |
Neck Pain |
5.0% |
Neutropenic Colitis |
5.0% |
Pancytopenia |
5.0% |
Respiratory Failure |
5.0% |
Sinus Bradycardia |
5.0% |
Vomiting |
5.0% |
|
Secondary |
Acute Myeloid Leukaemia |
26.6% |
Pyrexia |
13.0% |
Acute Promyelocytic Leukaemia |
10.5% |
Prophylaxis |
7.7% |
Myelodysplastic Syndrome |
5.5% |
Acute Lymphocytic Leukaemia |
4.8% |
Nausea |
4.6% |
Vomiting |
4.6% |
Product Used For Unknown Indication |
3.3% |
Chloroma |
2.6% |
Diffuse Large B-cell Lymphoma |
2.6% |
Acute Myelomonocytic Leukaemia |
2.4% |
Bipolar Disorder |
2.0% |
Body Temperature Increased |
2.0% |
Non-hodgkin's Lymphoma |
1.8% |
Acute Monocytic Leukaemia |
1.3% |
Infection Prophylaxis |
1.3% |
Pain |
1.3% |
Sleep Disorder |
1.1% |
Acute Leukaemia |
0.9% |
|
Sepsis |
10.0% |
Myalgia |
8.0% |
Vomiting |
8.0% |
Benign Intracranial Hypertension |
6.0% |
Condition Aggravated |
6.0% |
Myocardial Infarction |
6.0% |
Sinus Bradycardia |
6.0% |
Endocarditis |
4.0% |
Febrile Neutropenia |
4.0% |
Hepatic Function Abnormal |
4.0% |
Hepatocellular Injury |
4.0% |
Hyperbilirubinaemia |
4.0% |
Neutropenia |
4.0% |
Neutropenic Colitis |
4.0% |
Pleural Effusion |
4.0% |
Pneumonia |
4.0% |
Pulmonary Mycosis |
4.0% |
Septic Shock |
4.0% |
Venoocclusive Liver Disease |
4.0% |
Acute Febrile Neutrophilic Dermatosis |
2.0% |
|
Concomitant |
Acute Myeloid Leukaemia |
18.8% |
Product Used For Unknown Indication |
12.8% |
Acute Promyelocytic Leukaemia |
11.9% |
Prophylaxis |
10.6% |
Pyrexia |
4.6% |
Antifungal Prophylaxis |
4.2% |
Prophylaxis Of Nausea And Vomiting |
4.0% |
Prophylaxis Against Graft Versus Host Disease |
3.8% |
Acute Monocytic Leukaemia |
2.9% |
Allergy Prophylaxis |
2.9% |
Bone Marrow Conditioning Regimen |
2.7% |
Febrile Neutropenia |
2.7% |
Infection Prophylaxis |
2.7% |
Premedication |
2.7% |
Abdominal Pain |
2.2% |
Hypertension |
2.2% |
Insomnia |
2.2% |
Liver Abscess |
2.2% |
Herpes Zoster |
2.0% |
Vomiting |
1.8% |
|
Interstitial Lung Disease |
22.2% |
Vomiting |
11.1% |
Drug Ineffective |
6.7% |
Weight Increased |
6.7% |
Disseminated Intravascular Coagulation |
4.4% |
Febrile Neutropenia |
4.4% |
Neutropenia |
4.4% |
Pancreatitis Acute |
4.4% |
Renal Failure |
4.4% |
Respiratory Failure |
4.4% |
Syncope |
4.4% |
White Blood Cell Count Decreased |
4.4% |
Acute Graft Versus Host Disease In Skin |
2.2% |
Bronchitis |
2.2% |
Coagulopathy |
2.2% |
Drug Administration Error |
2.2% |
Drug Resistance |
2.2% |
Eosinophilic Pneumonia |
2.2% |
Hiccups |
2.2% |
Hyperbilirubinaemia |
2.2% |
|
Interacting |
Acute Myeloid Leukaemia |
31.3% |
Prophylaxis |
15.6% |
Febrile Neutropenia |
9.4% |
Pain |
9.4% |
Drug Use For Unknown Indication |
6.3% |
Anxiety Disorder |
5.2% |
Nausea |
5.2% |
Oedema |
5.2% |
Vomiting |
5.2% |
Antifungal Prophylaxis |
4.2% |
Menorrhagia |
3.1% |
|
Drug Interaction |
30.0% |
Cerebellar Syndrome |
20.0% |
Dysarthria |
20.0% |
Menorrhagia |
20.0% |
Device Occlusion |
10.0% |
|